Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Topper James N
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Parikh Asit
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director COLA MICHAEL F
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director FIELDS HEIDI
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director KARBE FRANK
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Stenhouse Mark
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Socks David A
Phathom Pharmaceuticals | 8-K: Current report
Phathom Pharmaceuticals | 10-Q: Quarterly report
Phathom Pharmaceuticals | 8-K: Phathom Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Phathom Pharmaceuticals | DEF 14A: Definitive information statements
Phathom Pharmaceuticals | DEFA14A: Others
Phathom Pharmaceuticals | ARS: Annual Report to Security Holders
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Henderson Molly
Phathom Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(4.8%)
Phathom Pharmaceuticals | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Takeda Pharmaceutical Company Limited(5.4%)
Phathom Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Curran Terrie
Phathom Pharmaceuticals | 10-K: Annual report
Phathom Pharmaceuticals | 8-K: Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Phathom Pharmaceuticals | 8-K: Current report
No Data